Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05526430 · ClinicalTrials.gov registry record · Phase 1
Study of Harmine in Healthy Subjects
A Phase 1 study, sponsored by James Murrough.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT05526430 is a Phase 1 study that has completed, run by James Murrough. The registered enrollment target is 27 participants.
The verdict
NCT05526430, a Phase 1 study, has completed, sponsored by James Murrough.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.
Interventions
- DRUG Harmine Hydrochloride Capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2022-09-13 |
| Est. Completion | 2023-06-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05526430
The ClinicalTrials.gov registry entry for NCT05526430 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James Murrough, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Harmine Hydrochloride Capsules is the first listed.
NCT05526430 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05526430 about?
NCT05526430 is a clinical study titled "Study of Harmine in Healthy Subjects". The present study is a phase 1 dose escalation study of harmine in healthy volunteers. The primary goal of the trial is to determine the maximum tolerated dose of harmine.
What is the current status of trial NCT05526430?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2022-09-13. Estimated completion is 2023-06-23.
What interventions are being tested in trial NCT05526430?
The interventions under investigation include: Harmine Hydrochloride Capsules (DRUG).
Who is sponsoring clinical trial NCT05526430?
This trial is sponsored by James Murrough, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.